Cartilage Regenerating therapy, Invossa, pulled from market despite lack of evidence of harm

The health authorities canceled the license for Kolon Life Sciences' osteoarthritis gene therapy drug Invossa, Tuesday, over the mislabeling of a key ingredient. In addition, they have decided to pursue criminal charges against the pharmaceutical firm.Invossa was the first regenerative gene therapy drug for patients with the degenerative joint disease. The Ministry of Food and Drug Safety approved it use in Korea...

Inhibiting Macrophage Death May Offer New Therapy for Rheumatoid Arthritis

A collaborative study by research groups from the University of Cologne, VIB, Ghent University, the Βiomedical Sciences Research Center ‘Alexander Fleming’ in Athens and the University of Tokyo identified a new molecular mechanism causing rheumatoid arthritis. The researchers found that death of macrophages, an immune cell type, can trigger the disease. Moreover, they discovered how the protein A20...

Stanford University finds that mast cells are crucial to causing osteoarthritis

Stanford University School of Medicine scientists have definitively linked mast cells, a class of cells belonging to the immune system, to the development of osteoarthritis, one of the world's most common causes of pain and immobility. ...

TPX-100 Delays Pathological Changes of Bone in Osteoarthritis of the Knee in phase 2 trial

OrthoTrophix, Inc. announced new analyses from a Phase 2 study of TPX-100, the company’s osteoarthritis (OA) drug candidate. The new results indicate slowing or halting of pathological bone shape changes, findings that support structural disease modification by TPX-100 treatment. Previous analysis demonstrated robust and statistically significant clinical benefits of the drug in moderate to severe knee OA.

Patients regain sensation and muscle function in affected limbs in early trial of CelGro nerve regeneration treatment

Orthocell Limited is running an early clinical trial with 20 patients and has reported that they have seen motor control restored in 4 of the patients who had a 'muscle power score of 0'. These initial 4 patients apparently reached a score of 4 ( 0-5 scale ), representing a 83% improvement. Results from the first trials are still ongoing....

Kolon Life Science’s stock plunges on Invossa cell labeling fiasco – and other developments.

The hits keep coming for Kolon Life Science. Early statements that the company was unaware that the GP-293 cells were present in the therapy appear to be falling apart. Export deals with Mundipharma and other companies have fallen apart, and a complete stop-sale is in place for the cartilage regenerating drug under suspicion that the GP-293 cells may be harmful,...

Medivir’s MIV-711 therapy for osteoarthritis shows disease modifying activity in phase 2 extension trial

Medivir presented the data on their Cathepsin K Inhibitor, MIV-711, at the OARSI conference over the weekend, and the results were a bit of a mixed bag but generally positive. Most therapies that regenerate cartilage and/or bone consist of single or multiple injections into the affected joint, and are long acting. Many of these therapies use growth factors, stem cells,...

Samumed Begins Phase 3 Lorecivivint (SM04690) Trial of Regenerative Therapy for Knee Osteoarthritis, Following Success of Phase 2 Trial

Samumed, LLC, announced today that it has finalized the design of its phase 3 clinical program of lorecivivint (SM04690) for the treatment of knee osteoarthritis (OA), which will observe the effects of lorecivivint on patient-reported outcomes and disease progression. The program will be referred to as STRIDES. Lorecivivint is a disease modifying drug that targets the WNT pathway. In the...